| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
Although some therapies for hepatocellular carcinoma (HCC) exist, tumor recurrence rate are extremely high in these patients after curative treatment. Among many strategies for HCC recurrence, dendritic cell (DC) based immunotherapy is promising cancer therapy. The success of this therapy depends on the function of induced DCs, but there has been no consensus on optimal conditions for DC preparation in vitro for immunotherapy of HCC patients. To address relevant issues, we evaluated the procedure to induce DCs that efficiently function in HCC patients. Using this methods, we have developed the dendritic cell-based immunotherapy combined with radiofrequency ablation for HCC and started clinical trial.
|
